• A non-biodegradable intra-ocular implant delivering precise controlled dose of two* Active Pharmaceuticals Ingredients (APIs) in the eye.


• Aimed to:
  • Reduce intra-ocular pressure and treat adult patients with primary open-angle glaucoma or ocular hypertension.
  • Strongly increase patient compliance and lower patient burden of daily medicating by removing undesirable side effects tide to the drug.


• Designed for minimum 2 years duration approval.


• Single intra-ocular implant in the shape of a flexible ring.


• Delivery of drugs close to action site provides an impressive reduction of dose and side effects compared to eye drops.


• Implantation:
  • With a specific injector (preloaded).
  • Minimally invasive surgery mimicked on a cataract surgery (possible at the same time).
  • Duration: 15 minutes in a one-day clinic visit.


• Development phase: discovery stage.

*Depending on the stage of glaucoma, a clinical treatment switch from one drug to a combination of drugs can be required.